For instance, the use of an anti-PD-L1 biomarker immunoassay on tumor tissues has been clinically validated and received FDA (Food and Drug Administration) approval for the prediction of response to first-line immunotherapy in certain cancer types [28,29]. The gene discussed is CD274; the disease is neoplasm.